Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib for recurrent acute anterior uveitis in axial spondyloarthritis
NL-OMON59774Phase 4Not yet recruiting
- Sponsor
- CARE Arthritis
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of upadacitinib in axial spondyloarthritis (axSpA) (2 arms), sponsored by CARE Arthritis. Primary endpoint: Change in exposure-adjusted acute anterior uveitis event rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
upadacitinib
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NL-OMON59774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59774.